ArticleGlobal health action2025
Operationalizing African self-reliance in vaccine manufacturing.
Article in Global health action, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccine equity in Africa: a rapid review of policy, legal and governance frameworks to improve research and development.Frontiers in health services · 2026Pooled it
- Global vaccine development.Nature medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic underscored Africa's urgent need for vaccine security and self-reliance. In response, the African Union and Africa Centers for Disease Control and Prevention (CDC) established the Framework for Action (FFA) through the Platform for Harmonized African Health Products Manufacturing (PHAHM), with a goal of 60% local vaccine production by 2040. During 2024, Africa CDC, Karolinska Institutet, and Charité Universitätsmedizin Berlin organized a seminar series to discuss advancing this agenda, including a multidisciplinary international expert panel. The series concluded that achieving this requires a comprehensive approach to addressing gaps in the ecosystem, including research and development (R&D), workforce development, technology transfer, regulatory systems, demand creation, and coordination. Strengthening R&D entails investment, capacity building, and equitable academic partnerships. A skilled workforce is essential, necessitating a coordinated approach through Regional Capability and Capacity Networks (RCCNs), training of vaccine manufacturing personnel, and academic programmes for sustainable workforce development. Technology transfer requires building trust between technology holders and recipients, alongside a supportive environment for knowledge exchange. Robust regulatory frameworks, including regional harmonization and strengthened National Regulatory Authorities (NRAs), are crucial for vaccine quality and safety, with the Africa Medicines Agency (AMA) providing oversight. Necessary market shaping through demand creation is achieved by advocating for procurement of locally produced vaccines, enhancing outreach for public trust, and operationalizing the African Pooled Procurement Mechanism (APPM). Coordination mechanisms are needed to optimize resource allocation, promote information sharing, and avoid redundancy. Strategic investments and policy support will be instrumental in achieving Africa's vaccine manufacturing aspirations and long-term health security.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.